KQED Nightly Business Report August 26, 2016
Heather bresch, the 18 million a year of mylan of epipen tried to shift the blame on the lifesaving medication to insurers and drug benefit managers today. In an interview with cnbc, she also vowed to help reduce the cost of the emergency allergy drug for some people. As weve been reporting, the drugs retail price has risen more than 500 over the past decade, and that has causes a fierce reaction from customers on main street, lawmakers in washington and investors on wall street. Today Brian Sullivan asked mylans ceo the questions many want asking. Facing backlash from the government, the publ...